# Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes Mellitus

> **NCT00722917** · PHASE2 · TERMINATED · sponsor: **Takeda** · enrollment: 323 (actual)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** TAK-379
- **DRUG:** TAK-379
- **DRUG:** TAK-379
- **DRUG:** Pioglitazone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00722917
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-07
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 323 (ACTUAL)
- **Why stopped:** Animal Toxicity Findings
- **Last updated:** 2016-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00722917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00722917, "Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00722917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*